A decision on ivonescimab — a PD-1/VEGF bispecific antibody developed in China by Akeso and co-developed for ex-China markets with Summit Therapeutics — is expected from the US FDA around 14 November 2026, according to industry reporting on the filing. As of this writing, no outcome had been published by the agency. The application covers ivonescimab combined with chemotherapy for non-small-cell lung cancer that progressed after a third-generation EGFR tyrosine kinase inhibitor, submitted as a Biologics License Application in January 2026.
For international patients evaluating cancer treatment in China, the announcement matters less for what it says about one molecule than for what it exposes: the same China-developed drug can be sitting in a hospital pharmacy in one country, queued inside a regulator's review in another, and reachable only through a clinical trial in a third. This page is deliberately written to stay useful on both sides of the decision. Nothing here replaces a clinical opinion; any treatment plan must be assessed in person by a licensed physician who has seen your pathology, molecular and imaging records.
What the 14 November decision actually changes
If the FDA approves, the practical effect in the United States is to create the legal basis for prescribing within the approved indication. It does not automatically put the drug on a formulary, into every hospital pharmacy, or into insurance coverage. Reimbursement review, site contracting and stocking decisions routinely add weeks or months between an approval and the first patient dose, and the indication wording on a US label can be narrower than the indication discussed in a press release.
If the FDA defers or declines, the molecule does not disappear. Patients already receiving it under a Chinese approval, or enrolled in trials registered in China, are unaffected in the short term, and the ex-China development programme now sits with a Western partner who may refile.
What neither outcome changes is the underlying pattern that makes this case worth reading about on its own. Chinese-origin oncology drugs are no longer hypothetical for Western systems. The same report notes that BeiGene's zanubrutinib generated RMB 9.424 billion in global sales across the first three quarters of 2026, up 27.0% year on year, with RMB 6.816 billion of that in the United States, up 29.4% — growth that traces back to a January 2023 FDA approval in chronic lymphocytic leukaemia. The company reported adjusted net profit of RMB 9.643 billion for the same period, up 103.9%.
The access gap: one molecule, three different queues
The gap between markets is not a scandal; it is a structural feature of drug regulation. Access in any country runs through one of three doors, and the doors open at different times:
- Approved and prescribable. The drug is licensed for a stated indication and stocked by hospitals. Eligibility is defined by the label.
- Approved, but not covered. Licensed, yet constrained by reimbursement and hospital procurement. Access becomes a case-by-case negotiation.
- Trial or special-access only. No marketing approval. Eligibility is defined by the protocol's inclusion and exclusion criteria, which are not harmonised between countries.
The important consequence for patients: the same person can be eligible through one door in one country and have no equivalent door in another. This is why "is it approved in the US yet?" is frequently the wrong question. The more useful questions are "is it approved anywhere, for my exact subtype, and can I be treated under that approval?" and "which trial, in which country, currently matches my history?"
Why the Chinese side of the queue is often shorter
China's regulatory pathway for oncology has accelerated-review mechanisms, and a large domestic clinical development base means many lung-cancer programmes reach their Chinese filings ahead of their Western ones. The 2026 licensing wave reinforces the direction of travel: a report from Huxiu on the China International Import Expo describes AstraZeneca completing a global exclusive licence with Dizal Pharma in September 2026 for a lung-cancer drug — with a US$600 million upfront payment and up to US$900 million in potential milestones plus royalties — for an agent that is already approved in both China and the United States for non-small-cell lung cancer driven by specific EGFR mutation types. That is the cleanest available illustration: a China-developed molecule can reach both markets, but not necessarily at the same time, not with the same label, and not with the same cost to the patient.
The same exhibition cycle covered by that report listed further transfers of China-origin assets to Western commercial machinery: a Sanofi stand showing a Chia Tai Tianqing cancer drug licensed for a US$135 million upfront and up to roughly US$1.4 billion in potential milestones with tiered royalties, and a Pfizer stand showing an injectable metabolic agent from Sciwhin. The licensing report adds that Hutchmed agreed a licence with GSK on 3 September 2026, that Hengrui and Novo Nordisk agreed a deal worth up to US$2.6 billion on 29 September 2026, and that Sino Biopharm and Boehringer Ingelheim announced a transaction worth up to US$7 billion on 4 November 2026 — with the expo report specifying US$358 million in upfront and near-term payments across six preclinical oncology programmes spanning antibody-drug conjugates and T-cell engagers.
Comparing the realistic routes for a lung cancer patient
The table below compares pathways by gatekeeping, expected sequence and cost structure rather than by promising figures. Timelines vary by site and product; treat the sequence, not the number of days, as the point.
| Route | Who controls eligibility | Typical sequence to first dose | Cost structure | Best suited to |
|---|---|---|---|---|
| Approved drug at home | National label plus local reimbursement rules | Prescription, then formulary or prior-authorisation review, then pharmacy dispensing | Largely insurer-driven; out-of-pocket depends on your plan | Patients whose subtype fits the label and whose insurer accepts it |
| Clinical trial at home | Protocol criteria and site capacity | Screening, eligibility review, waiting for an open slot | Investigational drug usually provided; tests and travel often not | Patients who meet a specific protocol and live near an enrolling site |
| Approved drug in China | Chinese label wording, confirmed against the treating hospital's stock | Records review, remote medical opinion, appointment, in-person assessment, treatment start | Hospital-quoted per cycle, generally far below Western list prices in the cases documented in our service pages | Patients whose drug is already marketed in China and not yet prescribable at home |
| Special / named-patient access | Treating physician plus regulator pathway | Physician application, approval, import logistics | Variable, often unbilled by insurers | Rare, disease-specific situations with no other route |
Two cautions on that middle-right row. First, price advantage is real but not universal and not fixed: it depends on the product, the number of cycles, supportive care, imaging and any concurrent surgery or radiotherapy. We do not publish a price for a regimen we have not quoted; the treating hospital's international department sets the actual number. Second, an approval in China does not mean approval in Europe, the UK or Australia — nor does it imply any of them will follow soon.
For patients whose situation involves cellular therapy rather than a bispecific antibody, the access arithmetic is different again; our CAR-T therapy in China page and the CAR-T cost breakdown explain how indication, manufacturing slot and hospital selection interact. Radiation-based options work on yet another clock — see proton therapy in China and the proton therapy guide, where equipment availability and queue length are the binding constraints rather than a marketing approval.
How to verify whether your drug is already available in China
Run this check before you decide anything about travel. It takes an afternoon, and it prevents most of the expensive misunderstandings.
- Find the generic name, not the brand name. Brand names differ between markets and the same string of letters can mean different products.
- Search the regulator's public approval record. Confirm an approval number exists, and read the indication sentence word for word. Mutation subtypes are often specified at the exon or variant level.
- Compare label versions. The Chinese package insert and a Western one can differ in approved indication, dosing, combination partners and listed warnings. This is the most under-checked item in the whole process.
- Confirm stock, not just approval. Ask the specific hospital whether their pharmacy currently supplies that product, since approval and inventory are separate facts.
- Check the trial map. If the drug is unapproved everywhere, look for registered trials in China as well as at home — eligibility criteria are not harmonised, and prior-line requirements in particular often differ.
- Get a written remote medical opinion from the treating centre based on your pathology, molecular panel and imaging files before booking flights.
If you want the records-side detail handled properly, our medical records for cancer treatment in China checklist covers what a Chinese oncology department needs and in what form. Our hospital appointment service in Shanghai exists for step 4 and 6 specifically.
What could go wrong — read this part twice
A news-driven article about drug access should spend as long on the failure modes as on the opportunity.
- You travel for a drug you were never eligible for. Label wording, organ function thresholds and prior-line counts exclude people. A remote review of your actual reports is the only reliable filter.
- Continuity of care breaks. If you start a regimen in China and need to continue at home, a home prescriber must be willing to accept the records and the product must be obtainable locally. Settle this in writing before the first dose.
- Complications happen away from your usual team. Hospitalisation, infection management and adverse-event handling abroad carry their own cost and coordination burden.
- The regulatory news does not go your way. A deferral or a decision for a narrower indication than expected changes the plan without notice. Build the trip so that a change on 14 November does not waste the flights.
- Insurance treats it as elective. Cross-border treatment is frequently self-funded even when the same drug class is covered domestically.
- You may not be well enough to travel. Advanced disease, poor performance status, or a need for continuous specialist support can make relocation the wrong therapeutic trade even when a drug is available abroad. For patients over 60 we set out the specific fitness questions in medical tourism for seniors alongside the general medical tourism guide, and the visa mechanics are covered in the China medical visa guide.
The honest summary: travelling for a drug that is already marketed somewhere is a rational response to an access gap, not a shortcut around medical judgement. It is worth investigating when the molecule, your subtype and your fitness all line up, and not worth it otherwise.
How to use the two windows around this news date
If the FDA approves on or near 14 November
The first question is not "can I get it at home?" but "when can I get it at home?" Approval, coverage and stocking land at different times. Meanwhile, a China approval for the same class of agent already defines a real clinical option for patients whose subtype fits. Expect more patients, more quickly, to weigh travel for lung-cancer treatment in China over the following months.
If the decision slips or is declined
Nothing about the Chinese availability changes. The ex-China programme's owner may refile or amend the indication. Patients whose clinical situation is time-sensitive should not build a plan on a hoped-for regulatory date in a third country — build it on what is currently prescribable and where.
Either way
The decision that matters for you is local: does an approved drug in some market match your exact molecular subtype, and can a qualified team see your records before you commit to travel? Our oncology treatment in China page explains how we route cases to departments that actually handle that tumour type, and how to choose a hospital for cancer treatment in China covers the selection criteria; the hospital directory lists centres by specialty.
Getting a concrete answer for your own case
News tells you where a molecule stands. It does not tell you whether you are eligible, what a specific hospital would charge for your regimen, or how a first dose could be scheduled around your existing treatment lines. Those require your reports.
Send your pathology report, molecular testing panel and imaging studies for a confidential case evaluation at /case-evaluation. A clinician-led review will confirm whether a marketed drug in China plausibly fits your indication, what the realistic timeline and cost range would be from an actual hospital quotation, and what the handover plan back home should look like — before you spend money on travel. For questions about translation, appointments, accommodation logistics and coordinating with departments, use /inquiry or contact us. OriEast provides document translation, hospital appointment booking and on-the-ground care coordination for international patients, and we will tell you plainly when the answer is that travelling is not the faster path.